Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
NCT ID: NCT03613987
Last Updated: 2023-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2018-04-26
2022-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Work of Breathing During Non-invasive Ventilation in Premature Neonates
NCT02788110
Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants
NCT03137225
sNIPPV Versus NIV-NAVA in Extremely Premature Infants
NCT04068558
Does NIV-NAVA Improve Diaphragmatic Function in Preterm Infants
NCT05079412
Short Term Effects of Synchronized vs. Non-synchronized NIPPV in Preterm Infants.
NCT03289936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Specific Aims:
The specific aims are to determine whether:
1. sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV.
2. sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent.
Randomization:
ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme.
Extubation criteria:
1. Infant is receiving caffeine.
2. Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria:
* mean airway pressure (MAP) \< 8cmH20,
* FiO2 \< 0.4,
* pH \> 7.2, and
* pCO2 \< 70.
Intubation criteria:
Infants must be intubated if any of the following criteria occur:
1. One apneic event requiring positive pressure ventilation (PPV).
2. More than 6 apneic events requiring stimulation within a 6-hour period.
3. A deterioration in respiratory status as noted by any of the following criteria:
* pH \< 7.2,
* pCO2 \> 70,
* FiO2 \> 0.6,
4. Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy.
Data Collection:
Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate.
Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines).
During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations.
Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET.
MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P \< 0.05.
Power analysis:
Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group.
Anticipated timeline:
With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year.
The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD.
There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NIPPV
non synchronized non invasive positive pressure ventilation
No interventions assigned to this group
NAVA-NIPPV
synchronized non invasive positive pressure ventilation with NAVA
NAVA technology to synchronize NIPPV
Neurally adjust ventilator assist is used to synchronize the NIPPV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NAVA technology to synchronize NIPPV
Neurally adjust ventilator assist is used to synchronize the NIPPV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Babies born at 24-30 weeks gestation.
3. Babies who qualify for surfactant administration within 90mins of birth:
* FiO2 \> 0.4,
* nCPAP \> 6, with
* Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions.
Exclusion Criteria
2. Babies with congenital anomalies including neuromuscular disorder.
3. Babies who do not require intubation until 7 days of life.
24 Weeks
30 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lance Parton, MD
Role: PRINCIPAL_INVESTIGATOR
Westchester Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Westchester Medical Center
Valhalla, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Louie K, Amatya S, Alpan G, Parton LA. Non-Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NAVA) Improves Extubation Outcomes in Extremely Low-Birth-Weight Infants. Children (Basel). 2024 Sep 28;11(10):1184. doi: 10.3390/children11101184.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L12,175
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.